Stock Analysis of Akero Therapeutics Inc (AKRO)

Loading ...

Birds Eye View of Akero Therapeutics Inc

Birds's Eye

Technical Analysis of Akero Therapeutics Inc

Stock Analysis of Akero Therapeutics Inc (AKRO) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	AKRO
Close	19.92
Change	-0.810 / 3.91 %
Volume	457666
Vol Change	-34.00 / 0.0074 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Bearish
Growth Index	Poor Growth Stock
Value Index	Poor Value Stock
Profitability Index	Poor Profitability Stock
Stability Index	No Significant Stability

Fundamental View of Akero Therapeutics Inc

PE (TTM)

-1445.58

Very Poor

Price / Book

448.75

Very Poor

Price / Sales

912505

Very Poor

Piotroski F Score

1.0

Very Poor

Market Cap

1377.49 M

Enterprise Value

1168.50 M

All Financial Ratio's

ROA (TTM)

-28.54

Very Poor

ROE (TTM)

-31.04

Very Poor

Net Margin (TTM)

-63123.94

Very Poor

Revenue

%

Net Profit

6.78 %

-119632.00 K

Debt to Equity

0.0471

Excellent

Altman Z Score

17.45

Excellent

Quick Ratio

0

Poor

Cash Ratio

28.75

Excellent

Financial Statement Analysis

Highs/Lows of Akero Therapeutics Inc

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	19.65	1.37 %	1.54 %	21.74	19.46	15-May-24	13-May-24
Two Week	19.66	1.32 %	3.42 %	22.26	19.46	06-May-24	13-May-24
One Month	21.6	7.78 %	5.60 %	22.26	18.2	06-May-24	25-Apr-24
Three Month	20.89	4.64 %	5.95 %	37.0	18.2	04-Mar-24	25-Apr-24
Six Months	15.62	27.53 %	17.48 %	37.0	15.32	04-Mar-24	06-Feb-24
One year	46.29	56.97 %	27.52 %	58.38	11.25	13-Jun-23	27-Oct-23
Two year	9.4	111.91 %	29.70 %	58.38	11.25	13-Jun-23	27-Oct-23

Technical View of Akero Therapeutics Inc

RSI

42.74

Neutral

MACD

-0.510

Bullish

ADX

29.31

Mild Bearish

Super Trend

22.76

Mild Bearish

Williams %R

-79.86

Neutral

CCI

-35.28

Neutral

Technical Analysis Deep Dive

EMA 5

20.43

Strong Bearish

EMA 15

20.62

Neutral

EMA 50

21.92

Strong Bearish

EMA 100

23.24

Mild Bearish

SMA 100

23.04

Mild Bearish

SMA 200

27.08

Strong Bearish

SMA 5 / 20

20.53 / 20.40

Strong Bearish

SMA 15 / 50

20.48 / 22.86

Mild Bearish

SMA 50 / 200

22.86 / 27.08

Mild Bearish

MA Analysis Deep Dive

Charts of Akero Therapeutics Inc

Returns of Akero Therapeutics Inc with Peers

Period / Stock	AKRO	PHR	ALHC	DNA
1 Week	1.37%	13.76%	6.30%	5.87%
1 Mth	-7.78%	4.97%	46.67%	-7.57%
3 Mth	-4.64%	-11.70%	9.34%	-45.20%
6mth	27.53%	54.74%	11.01%	-47.00%
1 Year	-56.97%	-22.55%	5.99%	-36.57%
2 Year	111.91%	52.13%	-25.54%	-70.60%
5 Years	-	-	-	-
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Akero Therapeutics Inc with Peers

Ratio / Stock	AKRO	PHR	ALHC	DNA
PE	-1445.58	-2440.31	-8.66	-1.69
P/B	448.75	1264.93	7.45	1.12
ROA	-28.54	-37.66	-22.20	-42.76
ROE	-31.04	-51.83	-86.48	-66.20
Debt To Equity	0.0471	0.0338	1.04	0.0182
Revenue	0 %	356299 K 26.84 %	1720.05 M 19.93 %	314985 K 34.06 %
Net Income	-119632.00 K 6.78 %	-136885.00 K 22.29 %	-157803.00 K 5.52 %	-856643.00 K 59.30 %

Technicals of Akero Therapeutics Inc with Peers

Technical / Stock	AKRO	PHR	ALHC	DNA	-
ADX	29.31	11.55	45.38	12.75
CMF	-0.112	-0.0038	0.200	-0.175
MFI	65.32	76.00	82.49	41.51
RSI	42.74	62.41	79.05	41.92
MACD Abv Signal	True	True	True	True
Price Above 50 MA	False	True	True	False	-
Price Above 200 MA	False	True	True	False	-

About : Akero Therapeutics Inc

Address : 601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Tel : 650 487 6488
URL : https://akerotx.com
Code : AKRO, ISIN : US00973Y1082, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 20_Jun_2019
Employee Count : 58

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Note : All Data Generated at the End of Trading Hours (EOD Data)